Toxicity and efficacy of sirolimus

Relationship to whole-blood concentrations

Herwig Ulf Meier-Kriesche, Bruce Kaplan

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: Sirolimus is a novel macrolide immunosuppressive drug with a mechanism of action distinct from that of both cyclosporine and tacrolimus. Recent clinical studies have demonstrated a decrease in acute rejection episodes in renal transplant patients receiving sirolimus compared with controls. The major toxicities associated with sirolimus treatment are thrombocytopenia and hyperlipidemia. In addition, concern has been raised by the higher serum creatinine levels noted in patients receiving sirolimus and cyclosporine compared with controls receiving cyclosporine and azathioprine. Objective: The objective of the present review is to summarize the efficacy and toxicity data for sirolimus. Special consideration is given to evidence that links these effects to dose or whole-blood concentrations of sirolimus. Results: The literature indicates that trough concentrations of sirolimus >15 ng/mL appear to be associated with a greater risk of both thrombocytopenia and hyperlipidemia, whereas trough sirolimus concentrations

Original languageEnglish (US)
JournalClinical Therapeutics
Volume22
Issue numberSUPPL. B
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Sirolimus
Cyclosporine
Hyperlipidemias
Thrombocytopenia
Macrolides
Azathioprine
Tacrolimus
Immunosuppressive Agents
Creatinine
Transplants
Kidney
Serum
Pharmaceutical Preparations

Keywords

  • Concentrations
  • Efficacy
  • Pharmacokinetics
  • Sirolimus
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology

Cite this

Toxicity and efficacy of sirolimus : Relationship to whole-blood concentrations. / Meier-Kriesche, Herwig Ulf; Kaplan, Bruce.

In: Clinical Therapeutics, Vol. 22, No. SUPPL. B, 2000.

Research output: Contribution to journalArticle

Meier-Kriesche, Herwig Ulf ; Kaplan, Bruce. / Toxicity and efficacy of sirolimus : Relationship to whole-blood concentrations. In: Clinical Therapeutics. 2000 ; Vol. 22, No. SUPPL. B.
@article{c10e87547a0548ad9239b7e874437359,
title = "Toxicity and efficacy of sirolimus: Relationship to whole-blood concentrations",
abstract = "Background: Sirolimus is a novel macrolide immunosuppressive drug with a mechanism of action distinct from that of both cyclosporine and tacrolimus. Recent clinical studies have demonstrated a decrease in acute rejection episodes in renal transplant patients receiving sirolimus compared with controls. The major toxicities associated with sirolimus treatment are thrombocytopenia and hyperlipidemia. In addition, concern has been raised by the higher serum creatinine levels noted in patients receiving sirolimus and cyclosporine compared with controls receiving cyclosporine and azathioprine. Objective: The objective of the present review is to summarize the efficacy and toxicity data for sirolimus. Special consideration is given to evidence that links these effects to dose or whole-blood concentrations of sirolimus. Results: The literature indicates that trough concentrations of sirolimus >15 ng/mL appear to be associated with a greater risk of both thrombocytopenia and hyperlipidemia, whereas trough sirolimus concentrations",
keywords = "Concentrations, Efficacy, Pharmacokinetics, Sirolimus, Toxicity",
author = "Meier-Kriesche, {Herwig Ulf} and Bruce Kaplan",
year = "2000",
doi = "10.1016/S0149-2918(00)89026-8",
language = "English (US)",
volume = "22",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "SUPPL. B",

}

TY - JOUR

T1 - Toxicity and efficacy of sirolimus

T2 - Relationship to whole-blood concentrations

AU - Meier-Kriesche, Herwig Ulf

AU - Kaplan, Bruce

PY - 2000

Y1 - 2000

N2 - Background: Sirolimus is a novel macrolide immunosuppressive drug with a mechanism of action distinct from that of both cyclosporine and tacrolimus. Recent clinical studies have demonstrated a decrease in acute rejection episodes in renal transplant patients receiving sirolimus compared with controls. The major toxicities associated with sirolimus treatment are thrombocytopenia and hyperlipidemia. In addition, concern has been raised by the higher serum creatinine levels noted in patients receiving sirolimus and cyclosporine compared with controls receiving cyclosporine and azathioprine. Objective: The objective of the present review is to summarize the efficacy and toxicity data for sirolimus. Special consideration is given to evidence that links these effects to dose or whole-blood concentrations of sirolimus. Results: The literature indicates that trough concentrations of sirolimus >15 ng/mL appear to be associated with a greater risk of both thrombocytopenia and hyperlipidemia, whereas trough sirolimus concentrations

AB - Background: Sirolimus is a novel macrolide immunosuppressive drug with a mechanism of action distinct from that of both cyclosporine and tacrolimus. Recent clinical studies have demonstrated a decrease in acute rejection episodes in renal transplant patients receiving sirolimus compared with controls. The major toxicities associated with sirolimus treatment are thrombocytopenia and hyperlipidemia. In addition, concern has been raised by the higher serum creatinine levels noted in patients receiving sirolimus and cyclosporine compared with controls receiving cyclosporine and azathioprine. Objective: The objective of the present review is to summarize the efficacy and toxicity data for sirolimus. Special consideration is given to evidence that links these effects to dose or whole-blood concentrations of sirolimus. Results: The literature indicates that trough concentrations of sirolimus >15 ng/mL appear to be associated with a greater risk of both thrombocytopenia and hyperlipidemia, whereas trough sirolimus concentrations

KW - Concentrations

KW - Efficacy

KW - Pharmacokinetics

KW - Sirolimus

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0034070977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034070977&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(00)89026-8

DO - 10.1016/S0149-2918(00)89026-8

M3 - Article

VL - 22

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - SUPPL. B

ER -